Suppr超能文献

[明显甲状腺功能亢进及自主性甲状腺肿伴甲状腺功能正常的放射性碘治疗结果]

[Results of radioiodine therapy of manifest hyperthyroidism and autonomous struma with euthyroidism].

作者信息

Berding G, Schicha H

机构信息

Radiologische Universitätsklinik, Abteilung Nuklearmedizin, Heidelberg, BR Deutschland.

出版信息

Nuklearmedizin. 1990 Aug;29(4):158-65.

PMID:2216811
Abstract

In 200 patients follow-up examinations were performed up to one year after radioiodine therapy (RITh) with individual dose calculation. The mean applied dose was significantly lower in patients with immunogenic hyperthyroidism (Graves' disease) as compared to patients with non-immunogenic hyperthyroidism (disseminated/multifocal autonomy, HYDA). In Graves' disease the rate of recurrent hyperthyroidism was significantly higher and that of posttreatment hypothyroidism lower. Considering the high recurrence rate in Graves' disease a higher dose, e.g. 150 Gy, seems to be appropriate. In patients with HYDA who received antithyroid drugs during RITh, recurrence of hyperthyroidism appeared slightly more, and posttreatment hypothyroidism slightly less, frequent. The efficiency of RITh was not significantly reduced by additional treatment with antithyroid drugs. Posttreatment hypothyroidism in patients with euthyroid goiter and disseminated/multifocal autonomy (EUDA) occurred significantly more frequent if the basal TSH level was greater than or equal to 0.5 muIE/ml before therapy. The goiter size was reduced independent of the basal TSH level. In this group protection by thyroxine could avoid posttreatment hypothyroidism without impairing the reduction of goiter. In HYDA patients after thyroid surgery recurrence appeared less, and in those with EUDA posttreatment hypothyroidism significantly more, frequent. A lower dose seems to be suitable in patients who underwent thyroid surgery before. In patients with focal autonomy after RITh no recurrence of hyperthyroidism was observed. In 9% a suppressed basal TSHh level indicating persistent autonomy was seen. Posttreatment hypothyroidism in focal autonomy appeared only in patients without manifest hyperthyroidism before RITh and was significantly more frequent in this group as compared to the other groups of patients.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

对200例患者在放射性碘治疗(RITh)后进行了长达一年的随访检查,并进行了个体化剂量计算。与非免疫性甲状腺功能亢进症(弥漫性/多灶性自主性,HYDA)患者相比,免疫性甲状腺功能亢进症(格雷夫斯病)患者的平均应用剂量显著更低。在格雷夫斯病中,甲状腺功能亢进症复发率显著更高,治疗后甲状腺功能减退症发生率更低。考虑到格雷夫斯病的高复发率,较高剂量,例如150 Gy,似乎是合适的。在RITh期间接受抗甲状腺药物治疗的HYDA患者中,甲状腺功能亢进症复发略显频繁,治疗后甲状腺功能减退症则略显不那么频繁。抗甲状腺药物的额外治疗并未显著降低RITh的疗效。如果治疗前基础促甲状腺激素(TSH)水平大于或等于0.5 μIU/ml,甲状腺肿和弥漫性/多灶性自主性(EUDA)患者治疗后甲状腺功能减退症的发生率显著更高。甲状腺肿大小的缩小与基础TSH水平无关。在该组中,甲状腺素的保护作用可避免治疗后甲状腺功能减退症,而不影响甲状腺肿的缩小。甲状腺手术后的HYDA患者复发较少,而EUDA患者治疗后甲状腺功能减退症显著更频繁。对于之前接受过甲状腺手术的患者,较低剂量似乎是合适的。在RITh后有局灶性自主性的患者中,未观察到甲状腺功能亢进症复发。9%的患者基础TSH水平受到抑制,表明存在持续性自主性。局灶性自主性患者的治疗后甲状腺功能减退症仅出现在RITh前无明显甲状腺功能亢进症的患者中,且与其他患者组相比,该组显著更频繁。(摘要截选至250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验